- Published on
Toxicology – Tolazoline
⸻
Core Concept
Tolazoline is an imidazoline-derived, nonselective α-adrenergic antagonist and vasodilator that is structurally related to phentolamine. Historically it was used as a systemic vasodilator for persistent pulmonary hypertension of the newborn (PPHN) and peripheral vascular disease.
The major toxicologic sequence is:
Tolazoline → α-adrenergic blockade + direct vasodilation ± histaminergic effects → systemic vasodilation → hypotension + reflex/direct tachycardia + GI hypersecretion/hypermotility
Severe toxicity may produce:
Profound hypotension, shock, tachyarrhythmia, metabolic acidosis, renal hypoperfusion, seizures, and GI hemorrhage.
The most important modern correction is that tolazoline is now largely a historical human drug. FDA withdrew approval of the human Priscoline NDA in 2009 after the manufacturer reported that the product was no longer marketed. Current U.S. DailyMed listings are for bulk tolazoline hydrochloride intended for animal-drug compounding, not a currently marketed human systemic product.
⸻
Current Status
The historical brand Priscoline was a human tolazoline product.
FDA formally withdrew approval of Priscoline in June 2009 after the sponsor stated that the product was no longer marketed and requested withdrawal.
As of 2026, a current DailyMed tolazoline hydrochloride listing identifies the product specifically as:
Bulk ingredient for animal drug compounding
rather than a human prescription product.
Tolazoline therefore belongs primarily in modern toxicology as a legacy medication and veterinary exposure, rather than as a routinely prescribed human drug.
⸻
Veterinary Use
Tolazoline remains clinically relevant in veterinary medicine.
U.S. regulations approve injectable tolazoline for use in horses to reverse sedation and analgesia produced by xylazine. The labeled veterinary dose is 4 mg/kg IV.
This means that modern human exposures may occasionally arise through:
Veterinary workplaces, accidental self-injection, compounding errors, or access to animal formulations.
⸻
Historical Human Uses
Tolazoline was formerly used for:
Persistent pulmonary hypertension of the newborn
Peripheral vascular disease
Pulmonary hypertension after cardiac surgery
and occasionally other vasospastic conditions.
Historical neonatal dosing often involved an IV loading dose around 1–2 mg/kg, followed by continuous infusion. Such dosing was associated with frequent hypotension and GI toxicity.
These historical doses should not be interpreted as current treatment recommendations.
⸻
Tolazoline and Modern PPHN Therapy
Tolazoline has been superseded in neonatal pulmonary hypertension.
Current PPHN management centers on:
Optimal ventilation and lung recruitment
Oxygenation
Inhaled nitric oxide (iNO)
with selected use of:
Sildenafil, prostacyclin analogues, milrinone, and ECMO
depending on physiology and treatment response. Current evidence-based recommendations identify iNO as established pulmonary vasodilator therapy for appropriate term and near-term infants with PPHN and hypoxemic respiratory failure.
Thus:
Tolazoline is not a contemporary first-line pulmonary vasodilator for PPHN.
⸻
Mechanism of Action
The old description of tolazoline as simply a competitive α-receptor antagonist is directionally correct but incomplete.
Tolazoline antagonizes α-adrenergic receptors, including α₂ receptor subtypes, and has historically been classified as a nonselective α-blocking vasodilator. Modern pharmacologic data confirm measurable antagonist activity at human α₂A, α₂B, and α₂C receptors.
The principal cardiovascular sequence is:
α-receptor blockade → reduced vasoconstrictor tone → peripheral vasodilation → reduced systemic vascular resistance → hypotension
Reflex sympathetic activity and additional cardiac actions contribute to tachycardia.
⸻
Histamine-Like Actions
Tolazoline is pharmacologically more complicated than a pure α-blocker.
Experimental studies found that tolazoline can produce histamine H₂-like effects, including vasodilation, cardiac stimulation, and increased gastric acid secretion. Some experiments support direct H₂ receptor activation, while other work suggests release of endogenous histamine may contribute.
This helps explain several characteristic adverse effects:
Tachycardia
Flushing
Increased gastric acid secretion
GI irritation/ulceration
⸻
Gastric Acid Secretion
Tolazoline has a particularly important historical GI toxicity.
It increases gastric acid secretion through histaminergic pathways, which contributed to:
Epigastric pain
Gastritis
GI bleeding
Duodenal ulceration
and, in severe neonatal cases:
Duodenal perforation
Multiple neonatal case reports documented ulceration and perforation during tolazoline treatment.
This was one of the practical disadvantages that helped make tolazoline unattractive once safer pulmonary vasodilators became available.
⸻
Toxic Dose
There is no validated human toxic-dose threshold.
Most human toxicity data derive from therapeutic adverse effects, especially neonatal IV treatment, rather than intentional oral overdose.
Therefore:
No single mg/kg threshold can reliably define a safe versus toxic human exposure.
Severity depends on:
Route
Rate of administration
Age
Renal function
Underlying cardiopulmonary disease
Degree of α-blockade
and
Coexposures
Rapid IV administration is especially concerning because systemic vasodilation can occur abruptly.
⸻
Pharmacokinetics
Tolazoline elimination can be substantially prolonged in neonates.
A neonatal pharmacokinetic study found a median half-life of approximately 4.4 hours, but the range was extremely broad—from about 1.5 to more than 40 hours. Half-life increased as urine output declined.
Therefore:
Oliguria can markedly prolong tolazoline exposure.
This is especially important because hypotension itself can impair renal perfusion, producing a cycle of reduced clearance and prolonged toxicity.
⸻
Renal Elimination
Tolazoline is substantially eliminated through the kidneys.
Historical neonatal experience showed that reduced urine output correlated with markedly prolonged elimination.
Renal function and urine output should therefore be monitored closely after significant systemic exposure.
⸻
Clinical Toxidrome
The characteristic acute syndrome is:
Vasodilation + tachycardia + hypotension + flushing + GI hyperactivity
More severe poisoning can progress to:
Shock + metabolic acidosis + renal hypoperfusion + dysrhythmia ± seizures
Because the drug has several receptor effects, both hypotension and paradoxical hypertension have historically been described.
⸻
Hypotension
Hypotension is the most important acute toxic effect.
Mechanisms include:
α-mediated loss of vascular tone
Direct vasodilation
Relative intravascular underfilling
and, in severe cases:
Reduced organ perfusion
Historical neonatal trials found hypotension more frequently when continuous tolazoline infusion followed an IV bolus.
⸻
Shock
Severe α-blockade may produce vasodilatory shock that is initially resistant to ordinary adrenergic support.
Tissue hypoperfusion may then produce:
Lactic/metabolic acidosis
Oliguria
Altered mental status
and potentially:
Multiorgan dysfunction
A veterinary overdose case provides mechanistic support for this pattern, with profound hypotension and metabolic acidosis after excessive IV tolazoline.
⸻
Tachycardia
Tachycardia results from several mechanisms:
Reflex sympathetic activation after vasodilation
plus possible:
Histamine-like cardiac stimulation
Experimental cardiac studies show that tolazoline can increase heart rate and myocardial contractility through H₂-related pathways.
⸻
Dysrhythmias
Cardiac dysrhythmias have been reported during therapeutic exposure and are biologically plausible during significant poisoning because of:
Tachycardia
Hypotension
Myocardial oxygen imbalance
Electrolyte abnormalities
and direct pharmacologic cardiac stimulation.
Any significantly symptomatic patient should have continuous ECG monitoring.
⸻
Paradoxical Hypertension
Although tolazoline is principally a vasodilator, hypertension has occasionally been reported.
This may reflect complex direct cardiac effects, autonomic responses, dosing dynamics, or interactions with other vasoactive drugs.
Therefore:
Do not assume that hypertension excludes tolazoline toxicity.
⸻
Flushing and Sweating
Peripheral vasodilation commonly causes:
Warm skin
Flushing
Diaphoresis
and occasionally:
Piloerection
These findings are generally secondary to vasomotor and autonomic effects rather than an allergic reaction.
⸻
Gastrointestinal Toxicity
Common GI effects include:
Nausea
Vomiting
Abdominal discomfort
Diarrhea
and increased intestinal motility.
More serious complications historically included:
GI hemorrhage
Duodenal ulceration
and perforation, particularly in critically ill neonates receiving continuous infusion.
⸻
GI Hemorrhage
GI bleeding was sufficiently common during historical neonatal use to become a major recognized treatment complication.
In one randomized neonatal study, both hypotension and GI bleeding occurred more frequently with continuous infusion than after a single bolus.
Therefore hematemesis, melena, falling hemoglobin, or abdominal deterioration after tolazoline exposure warrants urgent GI evaluation.
⸻
Renal Toxicity
Tolazoline can cause oliguria and acute kidney injury, largely through renal hypoperfusion and altered renal vascular tone.
Historical neonatal pharmacology literature specifically described tolazoline as capable of producing intense renal vasoconstriction with reduced perfusion.
This apparent paradox—systemic vasodilation with adverse renal vascular effects—is another reason the drug was difficult to manage in neonates.
⸻
Hematuria
Hematuria has been described historically but is nonspecific.
In a hypotensive patient it should prompt evaluation for:
Renal ischemia
Traumatic catheterization
Coagulopathy
or another renal/urologic process.
⸻
Hematologic Effects
Thrombocytopenia and other blood dyscrasias have been reported historically but are not characteristic defining features of acute tolazoline overdose.
CBC testing is reasonable in clinically significant exposure, especially when GI bleeding is suspected.
⸻
Neurologic Effects
Neurologic symptoms in severe toxicity may include:
Anxiety
agitation
weakness
altered consciousness
and rarely:
seizures
Many severe neurologic effects are likely secondary to hypotension, cerebral hypoperfusion, or metabolic derangement rather than a distinctive primary neurotoxic mechanism.
⸻
Seizures
Seizures are uncommon but possible after severe systemic toxicity.
Treat with:
Benzodiazepines first-line
while simultaneously correcting:
Hypotension
hypoxia
glucose abnormalities
electrolyte abnormalities
and acidosis.
⸻
Metabolic Acidosis
The old chapter correctly recognizes metabolic acidosis as a potential complication.
In severe poisoning, acidosis should be interpreted primarily as a marker of:
Poor tissue perfusion
rather than as a specific direct acid-base effect of tolazoline.
Treat the shock state rather than administering bicarbonate reflexively for mild compensated acidosis.
⸻
Hyperchloremic Acidosis – Historical Neonatal Reports
Older neonatal literature described hyperchloremic metabolic abnormalities during tolazoline treatment.
However, critically ill neonates were often receiving large volumes of chloride-containing fluids and multiple therapies, making the mechanism difficult to attribute exclusively to tolazoline.
Modern management should classify the acid-base disturbance objectively rather than assume that every acidosis is a characteristic direct drug effect.
⸻
Alcohol Interaction
Historical pharmacology sources describe a mild disulfiram-like or alcohol-intolerance reaction with tolazoline.
A small human study reported tingling, warmth, and head fullness after alcohol ingestion during tolazoline administration, and later drug-interaction references continued to describe this phenomenon.
However:
The evidence is old and limited, and this interaction is now mainly of historical significance because human tolazoline use has essentially disappeared.
⸻
Diagnosis
There is no specific rapid diagnostic test for tolazoline poisoning.
Diagnosis rests on:
Known exposure + vasodilatory toxidrome + hemodynamic abnormalities
In a modern case, identify whether the product is:
Veterinary tolazoline
Bulk compounded material
or an old/foreign human formulation.
⸻
Initial Assessment
For clinically significant exposure obtain:
Vital signs
12-lead ECG
continuous cardiac monitoring
glucose
electrolytes
bicarbonate
BUN/creatinine
and, when shock is present:
blood gas and lactate
CBC is useful when GI bleeding or another blood dyscrasia is suspected.
⸻
Drug Concentrations
Tolazoline concentrations are not routinely available and there is no validated human serum concentration associated with a defined toxic syndrome.
Therefore:
A tolazoline level is not needed for routine bedside management.
Treat the clinical physiology.
⸻
Differential Diagnosis
The differential for hypotension plus tachycardia includes:
Other α-blockers
vasodilators
calcium-channel blockers
tricyclic antidepressants
sepsis
hemorrhage
anaphylaxis
sedative coexposure
and other causes of distributive shock.
In veterinary workers, possible coexposures include:
Xylazine
detomidine
or other α₂-agonist sedatives.
These can produce an almost opposite initial syndrome of CNS depression, bradycardia, hypotension, miosis, and respiratory depression, making exposure history particularly important.
⸻
Tolazoline and Clonidine Poisoning – Historical Claim
Tolazoline was historically proposed as an antidote to clonidine because clonidine and tolazoline have opposing actions at α₂ receptors.
However:
Tolazoline should not be considered a modern clonidine antidote.
A pediatric case series specifically found tolazoline ineffective in reversing clonidine overdose manifestations.
Modern clonidine labeling states that tolazoline has produced inconsistent results and is not recommended as first-line treatment.
⸻
Modern Clonidine Poisoning Management
If clonidine toxicity is the actual problem, treatment centers on:
Airway and respiratory support
IV fluids
atropine for clinically important bradycardia
vasopressors when necessary
and selective consideration of naloxone as an adjunct.
Tolazoline should not be sought out specifically for this purpose.
⸻
Tolazoline and Xylazine – Human Versus Veterinary Context
Tolazoline remains approved in horses as an antagonist to xylazine.
That veterinary indication should not automatically be extrapolated to human xylazine poisoning.
Current human xylazine literature acknowledges that α₂ antagonists, including tolazoline, have been discussed, but there is no FDA-approved human xylazine antidote and supportive care remains central.
Thus:
Veterinary antidote ≠ established human antidote.
⸻
Treatment – General Principles
There is no specific antidote to tolazoline itself.
Treatment consists of:
Stop exposure + support perfusion + treat dysrhythmia/seizure + monitor renal and GI complications
Most toxicity should improve as drug exposure declines if organ perfusion is maintained.
⸻
Gastrointestinal Decontamination
Because historic human tolazoline was often given IV and current exposure is predominantly veterinary/parenteral, GI decontamination is usually irrelevant.
For an unusual recent oral ingestion of a substantial amount:
Do not induce vomiting.
Routine gastric lavage is not recommended.
Single-dose activated charcoal could be considered selectively after a very recent substantial oral ingestion if the airway is intact and the formulation is appropriate, but there are no meaningful clinical data showing improved outcome specifically for tolazoline.
⸻
Dermal or Ocular Exposure
Bulk veterinary/compounding material may create occupational dermal or ocular exposure.
Remove contaminated clothing and wash skin with soap and water.
Irrigate eyes immediately with copious water or saline.
Systemic toxicity after intact-skin exposure has not been well characterized, but significant contamination warrants observation if symptoms develop.
⸻
IV or Accidental Self-Injection
Accidental parenteral injection is potentially much more concerning because it bypasses absorption barriers.
Such patients should undergo immediate:
Hemodynamic assessment
ECG monitoring
and observation for:
hypotension, tachycardia, flushing, GI symptoms, and altered consciousness.
A veterinary worker with an accidental large injection should be evaluated in a medical facility rather than simply observed at home.
⸻
Hypotension – Initial Therapy
Begin with cautious isotonic crystalloid when intravascular depletion or relative underfilling is present.
The old recommendation for:
10–20 mL/kg normal saline + Trendelenburg positioning
should be modernized.
Trendelenburg positioning is not a treatment for shock.
Fluid therapy should be guided by clinical response, cardiac status, urine output, bedside ultrasound when useful, and the risk of fluid overload.
⸻
Vasopressor Therapy
The older text recommends phenylephrine because tolazoline blocks α receptors.
That mechanistic reasoning remains understandable, but evidence is extremely limited.
A veterinary tolazoline overdose was successfully managed with phenylephrine plus IV fluids, supporting the concept that a direct α₁ agonist can overcome competitive α blockade when sufficient receptor reserve remains.
In human modern critical care, however:
Norepinephrine is generally a reasonable first-line vasopressor for persistent vasodilatory shock.
If hypotension remains refractory and the toxicologic mechanism strongly suggests α blockade, phenylephrine may be considered as an adjunct or alternative under intensive monitoring.
There is no robust comparative human trial to establish one pressor as uniquely superior in tolazoline poisoning.
⸻
Why Vasopressor Response May Be Unpredictable
Because tolazoline competitively antagonizes α receptors, ordinary catecholamine vasoconstriction can be blunted.
At the same time, drugs with substantial β₂ activity can theoretically worsen vasodilation if α-mediated constriction is blocked.
Therefore:
Titrate pressors to physiology rather than following a rigid historical dopamine-first or phenylephrine-only algorithm.
⸻
Dopamine – Historical Recommendation
The old statement that hypotension may be resistant to dopamine is pharmacologically plausible because high-dose dopamine depends partly on α-mediated vasoconstriction.
Modern shock practice generally does not favor dopamine as the default vasopressor anyway.
Thus:
Dopamine should not be the first-choice vasopressor for tolazoline-induced vasodilatory shock.
⸻
Epinephrine
Historical drug-interaction references describe potentially paradoxical blood-pressure responses when large tolazoline exposures are combined with strongly adrenergic drugs.
Because epinephrine has important β₁ and β₂ as well as α activity, its response may be unpredictable when α receptors are blocked.
Therefore:
Epinephrine is not the preferred routine vasopressor for isolated tolazoline-induced vasodilatory hypotension.
It remains appropriate in cardiac arrest or anaphylaxis, where established resuscitation indications override this pharmacologic concern.
⸻
Phenylephrine
Phenylephrine is a direct predominantly α₁ agonist.
It may be useful when:
Vasodilatory hypotension is severe
tachycardia is already substantial
and a primarily vasoconstrictive drug is desirable.
However, large doses may be needed when α receptors are competitively blocked, and excessive vasoconstriction once the blocker wears off is theoretically possible.
Use continuous BP monitoring in severe poisoning.
⸻
Fluid Overload
Historical neonatal management sometimes used invasive central filling-pressure monitoring because these infants were extremely vulnerable to:
pulmonary edema
right-heart dysfunction
and fluid overload.
Modern practice should use clinical examination and appropriate hemodynamic/echocardiographic assessment rather than routine right-heart catheterization simply because tolazoline exposure occurred.
⸻
Tachyarrhythmias
Treat unstable dysrhythmias according to standard ACLS/PALS principles.
Simple sinus tachycardia usually improves when:
hypotension, anxiety, hypovolemia, and the drug effect resolve.
Do not reflexively suppress compensatory sinus tachycardia with a beta-blocker in a hypotensive patient.
⸻
Bradycardia
Although tachycardia is more characteristic, bradycardia may occur in critically ill patients or due to coexposures.
Treat clinically significant bradycardia according to standard resuscitation principles, including correction of hypoxia and hypotension.
⸻
Seizure Treatment
For seizures:
Benzodiazepines are first-line.
Persistent seizures should be treated using standard toxicologic status-epilepticus management.
Simultaneously restore cerebral perfusion and correct severe metabolic abnormalities.
⸻
GI Bleeding
Treat clinically significant GI hemorrhage using contemporary GI-bleeding principles.
Obtain:
CBC
type and screen/crossmatch
coagulation studies
and provide blood products when clinically required.
Endoscopy should be guided by bleeding severity and patient stability.
⸻
H₂-Receptor Antagonists – Historical Interaction
A historical case reported that cimetidine given for tolazoline-associated GI bleeding was followed by worsening oxygenation, with the proposed mechanism being antagonism of tolazoline’s H₂-mediated pulmonary vasodilation.
This is now mainly a historical pharmacology observation, because tolazoline is no longer used as standard PPHN treatment.
It should not be generalized into a modern rule that H₂ blockers are dangerous in ordinary patients with remote tolazoline exposure.
⸻
Proton-Pump Inhibitors
There is no evidence that PPIs reverse tolazoline poisoning.
They may be appropriate for clinically significant acid-related upper-GI injury or hemorrhage according to standard GI indications.
⸻
Renal Failure
Monitor:
urine output
creatinine
electrolytes
and acid-base status.
Correct hypotension promptly because renal hypoperfusion can both worsen AKI and slow tolazoline elimination.
Dialysis should be used for conventional renal indications rather than assumed to be a drug-removal treatment.
⸻
Hemodialysis
There is no established evidence that hemodialysis provides clinically important enhanced elimination of tolazoline.
Therefore:
Hemodialysis is not routine treatment for tolazoline poisoning.
Use renal replacement therapy for conventional indications such as refractory acidosis, hyperkalemia, pulmonary edema, or severe renal failure.
⸻
Hemoperfusion and Plasma Exchange
There is no established role for:
Hemoperfusion
plasma exchange
or
forced diuresis
in tolazoline poisoning.
⸻
Pregnancy
Modern human pregnancy data are extremely limited because tolazoline has not been routinely used in people for many years.
There is no useful current FDA human pregnancy labeling to replace the old literature.
In a pregnant patient with significant accidental exposure:
Treat maternal hypotension, dysrhythmia, or respiratory compromise normally.
Maternal perfusion is central to fetal perfusion.
⸻
Breastfeeding
There are insufficient modern human data to define milk transfer or infant risk after tolazoline exposure.
After a substantial acute maternal exposure, breastfeeding decisions should be individualized with toxicology and pediatric/pharmacy input until maternal systemic effects have resolved.
⸻
Monitoring
Symptomatic patients should have:
Continuous blood-pressure and cardiac-rhythm monitoring
plus serial assessment of:
mental status
renal function
urine output
electrolytes
and acid-base status.
Significant GI symptoms warrant CBC monitoring for occult bleeding.
⸻
Observation
The historical fixed 6-hour rule is not well validated.
For a truly small exposure with no symptoms and no parenteral injection, several hours of observation may be sufficient after poison-center assessment.
However, prolonged monitoring is appropriate when there is:
IV exposure
unknown amount
persistent tachycardia
hypotension
renal impairment
GI bleeding
seizure
or coexposure to veterinary sedatives.
Renal dysfunction may markedly prolong the drug’s half-life.
⸻
Admission
Hospital admission is appropriate for:
Persistent hypotension
significant tachyarrhythmia
GI bleeding
AKI/oliguria
metabolic acidosis
neurologic symptoms
or a substantial accidental parenteral exposure.
⸻
ICU Admission
ICU-level care is appropriate for:
Shock requiring vasopressors
Severe dysrhythmia
Seizure
Respiratory failure
severe metabolic acidosis
or major GI hemorrhage.
⸻
Prognosis
Most uncomplicated tolazoline adverse effects resolve as the drug is eliminated and vascular tone normalizes.
However, historical neonatal experience demonstrates that toxicity was not always benign; important complications included:
Profound hypotension
GI hemorrhage
duodenal ulceration/perforation
and renal impairment.
The prognosis after an isolated modern accidental exposure should generally be good when shock and complications are recognized early.
⸻
Important Pitfalls
The first major pitfall is assuming tolazoline remains a routine human medication.
Human Priscoline approval was withdrawn in the United States in 2009 after the product was no longer marketed.
Current U.S. tolazoline listings are principally veterinary or animal-compounding products.
⸻
Another pitfall is continuing to describe tolazoline as standard therapy for neonatal pulmonary hypertension.
Modern PPHN treatment uses iNO and other contemporary pulmonary vasodilator strategies—not tolazoline.
⸻
Do not describe tolazoline as a pure α blocker.
It also has histamine-like effects, which contribute to cardiac stimulation and gastric acid secretion.
⸻
Do not miss GI toxicity.
Tolazoline historically caused GI hemorrhage, duodenal ulceration, and even perforation in neonates.
⸻
Do not assume hypotension will always respond normally to catecholamines.
Competitive α blockade can make vasopressor response unpredictable.
Use norepinephrine or carefully titrated direct α-agonist support such as phenylephrine, guided by hemodynamics rather than an old dopamine-first algorithm.
⸻
Do not use Trendelenburg positioning as treatment for shock.
Volume resuscitation and vasopressors should be physiologically guided.
⸻
Do not use tolazoline as a routine antidote for clonidine poisoning.
Clinical reports found inconsistent or absent benefit, and current clonidine labeling does not recommend it as first-line therapy.
⸻
Similarly, do not assume that because tolazoline reverses xylazine in horses it is an established human xylazine antidote.
Veterinary approval does not establish human efficacy or safety.
⸻
The old disulfiram-like alcohol interaction has some historical experimental support, but it is now largely of legacy pharmacologic interest rather than a major modern clinical problem.
⸻
Finally, do not underestimate renal dysfunction.
Tolazoline half-life can become dramatically prolonged when urine output falls.
⸻
High-Yield Toxicology Pearls
Tolazoline = historical α-blocking vasodilator toxicity.
⸻
Its core toxicologic mechanism is:
α-adrenergic blockade → vasodilation → hypotension → reflex/direct tachycardia
with additional histamine-like cardiac and gastrointestinal actions.
⸻
The principal overdose syndrome is:
Flushing + tachycardia + hypotension + GI hypermotility ± shock
⸻
Severe poisoning may cause:
Metabolic acidosis + AKI/oliguria + dysrhythmia + seizure
⸻
Historical neonatal therapy frequently produced:
Hypotension + GI hemorrhage
and rare:
Duodenal ulceration/perforation
⸻
Tolazoline is no longer a standard human PPHN treatment. Modern PPHN care uses iNO and selected sildenafil, prostacyclin, milrinone, or ECMO strategies depending on physiology.
⸻
Human Priscoline approval was withdrawn in the United States in 2009 after it was no longer marketed.
⸻
Current U.S. tolazoline products are principally veterinary, including an FDA-regulated injectable product used in horses to reverse xylazine.
⸻
Veterinary xylazine antidote does not equal proven human xylazine antidote.
⸻
Tolazoline should also not be used as routine clonidine antidotal therapy; human pediatric reports found it ineffective or inconsistent.
⸻
There is:
No specific antidote for tolazoline toxicity.
⸻
Treatment is:
Stop exposure → cautious IV fluid → vasopressor for persistent shock → ECG/renal monitoring → treat seizures/GI bleeding supportively
⸻
For persistent vasodilatory shock:
Norepinephrine is a reasonable modern first-line vasopressor; phenylephrine may be useful when direct α₁ vasoconstriction is specifically desired.
Human comparative evidence specific to tolazoline is extremely limited.
⸻
Routine gastric lavage, forced diuresis, hemoperfusion, and hemodialysis for drug removal are not established therapies.
⸻
Tolazoline elimination may be highly variable in neonates and can become markedly prolonged with oliguria; historical half-lives ranged from roughly 1.5 to >40 hours.
⸻
The single most important modern warning is:
Tolazoline is now mainly a legacy/veterinary toxicology exposure—if a human patient is hypotensive after it, treat the vasodilatory shock rather than trying to resurrect its historical uses.